Effects and safety of pueraria mirifica gel on vaginal health and lower urinary tract in postmenopausal wome

Phase 2

• Conditions: rogenital atrophy; vaginal atrophy; urethral atrophy; urinary incontinence; pueraria mirifica

• Registration Number: TCTR20141013003
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2014-10-13
• Study Completion: 2014-11-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

postmenopausal women
urogenital atrophy

Exclusion Criteria

not willing to participate

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rethral cytology 4 weeks Maturation Index,Urethral blood flow 4 weeks Pulsatility index

Secondary Outcome Measures

Name	Time	Method
Vaginal cytology 4 weeks Maturation index